<code id='924ACCEED4'></code><style id='924ACCEED4'></style>
    • <acronym id='924ACCEED4'></acronym>
      <center id='924ACCEED4'><center id='924ACCEED4'><tfoot id='924ACCEED4'></tfoot></center><abbr id='924ACCEED4'><dir id='924ACCEED4'><tfoot id='924ACCEED4'></tfoot><noframes id='924ACCEED4'>

    • <optgroup id='924ACCEED4'><strike id='924ACCEED4'><sup id='924ACCEED4'></sup></strike><code id='924ACCEED4'></code></optgroup>
        1. <b id='924ACCEED4'><label id='924ACCEED4'><select id='924ACCEED4'><dt id='924ACCEED4'><span id='924ACCEED4'></span></dt></select></label></b><u id='924ACCEED4'></u>
          <i id='924ACCEED4'><strike id='924ACCEED4'><tt id='924ACCEED4'><pre id='924ACCEED4'></pre></tt></strike></i>

          explore

          explore

          author:hotspot    Page View:665
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          Brain technologies pose threats that are all too real, experts warn
          Brain technologies pose threats that are all too real, experts warn

          Inthe2011film"Limitless,"mysterypillsletBradleyCooper'sstrugglingwriteraccess100percentofhisbrain,ma

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Primary care doctor shortage won't be solved by free med school tuition

          AdobeLastmonth,nearly40,000medicalstudentswereacceptedintoresidencyprogramson“MatchDay.”Surroundedby